CAS 1414976-20-7
:Vazegepant HCl
Description:
Vazegepant HCl is a novel small molecule that acts as a selective antagonist of the calcitonin gene-related peptide (CGRP) receptor, which plays a significant role in the pathophysiology of migraine. This compound is characterized by its ability to inhibit CGRP signaling, thereby providing a mechanism for the acute treatment of migraine attacks. Vazegepant is typically administered in its hydrochloride salt form, enhancing its solubility and stability. The substance has been studied for its efficacy in reducing migraine frequency and severity, with a favorable safety profile. Its pharmacokinetic properties include rapid absorption and a relatively short half-life, making it suitable for acute migraine management. As a synthetic compound, Vazegepant HCl is subject to rigorous quality control and regulatory standards to ensure its purity and effectiveness. Overall, its targeted action on the CGRP pathway represents a significant advancement in migraine therapeutics, offering an alternative to traditional treatments.
Formula:C36H47ClN8O3
Synonyms:- gepant,CGRP Receptor,Zavegepant,Calcitonin gene-related peptide receptor,receptor,COVID-19,BHV3500,BHV-3500,BHV 3500,Vazegepant,inhibit,inflammation,migraine,intranasal,Inhibitor,Vazegepant hydrochloride,CGRP,soluble
- Vazegepant hydrochloride
- Vazegepant HCl salt
- Vazegepant HCl
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 4 products.
Vazegepant hydrochloride
CAS:<p>Vazegepant hydrochloride (Vazegepant HCl) is the first intranasal gepant for the acute treatment of migraine and has announced a positive phase II/III study.</p>Formula:C36H47ClN8O3Purity:98.93%Color and Shape:SolidMolecular weight:675.3
